United Therapeutics Stock Price Prediction
| UTHR Stock | USD 468.94 3.12 0.66% |
Momentum 43
Sell Extended
Oversold | Overbought |
Quarterly Earnings Growth 0.121 | EPS Estimate Next Quarter 6.5091 | EPS Estimate Current Year 27.0015 | EPS Estimate Next Year 28.5888 | Wall Street Target Price 530.835 |
Using United Therapeutics hype-based prediction, you can estimate the value of United Therapeutics from the perspective of United Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards United Therapeutics using United Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards United using crowd psychology based on the activity and movement of United Therapeutics' stock price.
United Therapeutics Short Interest
An investor who is long United Therapeutics may also wish to track short interest. As short interest increases, investors should be becoming more worried about United Therapeutics and may potentially protect profits, hedge United Therapeutics with its derivative instruments, or be ready for some potential downside.
200 Day MA 377.8221 | Short Percent 0.0566 | Short Ratio 4.02 | Shares Short Prior Month 2.1 M | 50 Day MA 485.5696 |
United Therapeutics Hype to Price Pattern
Investor biases related to United Therapeutics' public news can be used to forecast risks associated with an investment in United. The trend in average sentiment can be used to explain how an investor holding United can time the market purely based on public headlines and social activities around United Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of United Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about United Therapeutics.
United Therapeutics Implied Volatility | 0.44 |
United Therapeutics' implied volatility exposes the market's sentiment of United Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if United Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that United Therapeutics stock will not fluctuate a lot when United Therapeutics' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in United Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying United because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
United Therapeutics after-hype prediction price | USD 468.94 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current United contract
Based on the Rule 16, the options market is currently suggesting that United Therapeutics will have an average daily up or down price movement of about 0.0275% per day over the life of the 2026-04-17 option contract. With United Therapeutics trading at USD 468.94, that is roughly USD 0.13 . If you think that the market is fully incorporating United Therapeutics' daily price movement you should consider acquiring United Therapeutics options at the current volatility level of 0.44%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Check out United Therapeutics Basic Forecasting Models to cross-verify your projections. United Therapeutics After-Hype Price Density Analysis
As far as predicting the price of United Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in United Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of United Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
United Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting United Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on United Therapeutics' historical news coverage. United Therapeutics' after-hype downside and upside margins for the prediction period are 467.22 and 470.66, respectively. We have considered United Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
United Therapeutics is very steady at this time. Analysis and calculation of next after-hype price of United Therapeutics is based on 3 months time horizon.
United Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as United Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading United Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with United Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.21 | 1.72 | 1.55 | 0.06 | 8 Events / Month | 7 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
468.94 | 468.94 | 0.00 |
|
United Therapeutics Hype Timeline
United Therapeutics is at this time traded for 468.94. The entity has historical hype elasticity of -1.55, and average elasticity to hype of competition of -0.06. United is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is about 23.37%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is at this time at 0.21%. %. The volatility of related hype on United Therapeutics is about 653.99%, with the expected price after the next announcement by competition of 468.88. About 98.0% of the company outstanding shares are owned by institutional investors. The book value of United Therapeutics was at this time reported as 153.61. The company has Price/Earnings To Growth (PEG) ratio of 1.43. United Therapeutics recorded earning per share (EPS) of 26.4. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 23rd of September 2009. Given the investment horizon of 90 days the next forecasted press release will be in about 8 days. Check out United Therapeutics Basic Forecasting Models to cross-verify your projections.United Therapeutics Related Hype Analysis
Having access to credible news sources related to United Therapeutics' direct competition is more important than ever and may enhance your ability to predict United Therapeutics' future price movements. Getting to know how United Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how United Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| INCY | Incyte | 0.83 | 10 per month | 1.72 | 0.09 | 4.10 | (2.92) | 14.33 | |
| GMAB | Genmab AS | (0.62) | 12 per month | 1.86 | 0.05 | 4.09 | (3.16) | 9.07 | |
| RPRX | Royalty Pharma Plc | 0.97 | 14 per month | 1.47 | 0.06 | 2.13 | (2.28) | 12.26 | |
| DGX | Quest Diagnostics Incorporated | (3.06) | 9 per month | 0.00 | (0.1) | 2.68 | (2.28) | 6.29 | |
| ZBH | Zimmer Biomet Holdings | (1.35) | 8 per month | 0.00 | (0.13) | 2.92 | (2.20) | 18.45 | |
| THC | Tenet Healthcare | (5.05) | 8 per month | 0.00 | (0.07) | 3.14 | (3.00) | 14.80 | |
| ILMN | Illumina | 0.69 | 9 per month | 1.37 | 0.16 | 4.19 | (2.83) | 28.04 | |
| WST | West Pharmaceutical Services | 3.79 | 8 per month | 0.00 | (0.11) | 2.56 | (3.58) | 17.94 | |
| WAT | Waters | 0.65 | 9 per month | 0.87 | 0.09 | 3.35 | (1.83) | 8.38 | |
| BIIB | Biogen Inc | 0.52 | 24 per month | 1.62 | 0.1 | 3.11 | (2.55) | 9.61 |
United Therapeutics Additional Predictive Modules
Most predictive techniques to examine United price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for United using various technical indicators. When you analyze United charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About United Therapeutics Predictive Indicators
The successful prediction of United Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as United Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of United Therapeutics based on analysis of United Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to United Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to United Therapeutics's related companies. | 2025 | 2026 (projected) | Dividend Yield | 0.0129 | 0.0114 | Price To Sales Ratio | 6.37 | 6.06 |
Pair Trading with United Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with United Stock
Moving against United Stock
| 0.85 | MLEC | Moolec Science SA | PairCorr |
| 0.83 | DRMA | Dermata Therapeutics | PairCorr |
| 0.83 | PLX | Protalix Biotherapeutics | PairCorr |
| 0.83 | AMRN | Amarin PLC | PairCorr |
| 0.81 | CUE | Cue Biopharma | PairCorr |
| 0.79 | SPRB | Spruce Biosciences Common | PairCorr |
The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.
The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.